Engrail Therapeutics
PrivateLast Round
Series B
Extension
Aug 8, 2024
Total Funding Raised
$241M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Engrail Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B Extension round in August 2024.
Engrail Therapeutics is a clinical-stage pharmaceutical company that develops precision-targeted therapies for patients with neuropsychiatric and neurodevelopmental disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engrail Therapeutics Comparables
Compare Engrail Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Autobahn Therapeutics | 79% | |
| Neumora | 77% | |
| Alto Neuroscience | 75% |
For institutional investors. Book with your work email.
Engrail Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 8, 2024 | ||||
| Series B | Mar 19, 2024 | ||||
| Series A Extension | Aug 3, 2021 | ||||
| Series A | Jun 18, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Engrail Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B |
| abrdn Inc. | Series B |
| F-Prime Capital | Series B |
| Eight Roads Ventures | Series B |
| Ysios Capital | Series B |
| Nan Fung Life Sciences | Series A Extension, Series A |
| Norwest Venture Partners | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 45% MoM.
- Jul 16, 2025
ENX-101 evaluated for antiseizure effects in GAERS model.
For institutional investors. Book with your work email.
Engrail Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Engrail Therapeutics's valuation, stock price, and market status.
Is Engrail Therapeutics a public or private company?
Engrail Therapeutics is a private company.
What is the current stock price of Engrail Therapeutics?
Engrail Therapeutics is a private company, so its shares have no public market price. Caplight tracks Engrail Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Engrail Therapeutics worth (valuation)?
Valuation information for Engrail Therapeutics is not publicly available.
Can I buy Engrail Therapeutics stock?
Engrail Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Engrail Therapeutics's last funding round?
Engrail Therapeutics's most recent funding round was Series B Extension on August 8, 2024.
Who are the main investors in Engrail Therapeutics?
Key investors in Engrail Therapeutics include Forbion, F-Prime Capital, Nan Fung Life Sciences, Norwest Venture Partners, Pivotal bioVenture Partners.
Will Engrail Therapeutics IPO soon?
No public IPO plans have been announced for Engrail Therapeutics.
How can I track Engrail Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Engrail Therapeutics's shares on secondary markets.